| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTRB2 |
| Uniprot No | Q6GPI1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-263aa |
| 氨基酸序列 | CG VPAIHPVLSG LSRIVNGEDA VPGSWPWQVS LQDKTGFHFC GGSLISEDWV VTAAHCGVRT SDVVVAGEFD QGSDEENIQV LKIAKVFKNP KFSILTVNND ITLLKLATPA RFSQTVSAVC LPSADDDFPA GTLCATTGWG KTKYNANKTP DKLQQAALPL LSNAECKKSW GRRITDVMIC AGASGVSSCM GDSGGPLVCQ KDGAWTLVGI VSWGSRTCST TTPAVYARVA KLIPWVQKIL AAN |
| 预测分子量 | 27,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CTRB2重组蛋白的典型文献(模拟示例，非真实文献)：
1. **《Structural and functional characterization of recombinant CTRB2 protease》**
- 作者：Smith A, et al.
- 摘要：解析CTRB2重组蛋白的晶体结构，并验证其在体外对胰蛋白酶底物的催化活性，揭示其pH依赖性激活机制。
2. **《CTRB2 expression in pancreatic inflammation: Role of recombinant protein in disease modeling》**
- 作者：Chen L, et al.
- 摘要：通过大肠杆菌表达重组CTRB2.发现其在慢性胰腺炎患者血清中水平异常，提示其可能作为炎症进展的生物标志物。
3. **《Recombinant CTRB2 inhibits tumor growth via modulation of extracellular matrix remodeling》**
- 作者：Wang Y, et al.
- 摘要：利用哺乳动物细胞系统生产功能性CTRB2重组蛋白，证明其通过降解肿瘤微环境中的纤维连接蛋白抑制癌细胞侵袭。
4. **《Autoactivation mechanism of pro-CTRB2 studied by site-directed mutagenesis》**
- 作者：Kim H, et al.
- 摘要：通过重组蛋白突变体实验，揭示CTRB2前体的自激活关键位点及与遗传性胰腺病相关突变的影响。
---
注：以上为模拟文献，实际研究需通过PubMed等数据库检索(关键词：CTRB2 recombinant protein/expression)。真实文献可能涉及CTRB2在胰腺癌、糖尿病或遗传性胰腺炎中的功能研究。
**Background of CTRB2 Recombinant Protein**
CTRB2 (Chymotrypsinogen B2) is a pancreatic serine protease precursor primarily involved in digestive enzyme activation. Encoded by the *CTRB2* gene, it is synthesized in the acinar cells of the pancreas as an inactive zymogen, which is later cleaved by trypsin to form active chymotrypsin. This enzyme plays a critical role in protein digestion by hydrolyzing peptide bonds, particularly targeting aromatic amino acid residues.
Recombinant CTRB2 is produced using biotechnological platforms, such as *E. coli* or mammalian expression systems, to generate the protein in vitro. The recombinant form retains the structural and functional characteristics of the native protein, enabling studies on its enzymatic activity, substrate specificity, and regulatory mechanisms. Its production often includes tags (e.g., His-tag) for simplified purification via affinity chromatography.
Research on CTRB2 has gained attention due to its implications in pancreatic diseases. Mutations or dysregulation of CTRB2 are linked to chronic pancreatitis, pancreatic cancer, and other disorders. Additionally, CTRB2 variants have been associated with diabetes mellitus, suggesting a potential role in metabolic regulation. The recombinant protein serves as a tool for investigating disease mechanisms, screening protease inhibitors, and developing diagnostic biomarkers.
In structural biology, recombinant CTRB2 aids in elucidating protease activation pathways and substrate-binding interactions, providing insights for therapeutic drug design. Its applications extend to biotechnology, where engineered variants are explored for industrial protein processing. Overall, CTRB2 recombinant protein is a vital resource for advancing both basic research and clinical innovations in pancreatic biology and related pathologies.
(Word count: 246)
×
